Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

190
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
190
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

211
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
211
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

288
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
288
Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

278
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
278
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

309
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
309
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

304
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth patterns of ascending aortic aneurysms.

Journal of cardiothoracic surgery·2026
Same author

Autologous atrial appendage micrografts transplanted during coronary artery bypass surgery: design of the AAMS2 randomized, double-blinded, and placebo-controlled trial.

Trials·2026
Same author

Intraoperative complications during gastrectomy for gastric cancer - incidence, treatment, and effect on postoperative complications and survival in a population-based nationwide study.

Langenbeck's archives of surgery·2025
Same author

ASO Visual Abstract: Neoadjuvant Treatment and Postoperative Complications after Surgery for Esophageal Cancer: a Population-Based, Nationwide Study in Finland.

Annals of surgical oncology·2025
Same author

Body mass index and survival after surgery for gastric adenocarcinoma: a population-based nationwide cohort study in Finland.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2025
Same author

ASO Author Reflections: Neoadjuvant Treatment Does not Increase Postoperative Complications Compared with Upfront Surgery in Esophageal Cancer.

Annals of surgical oncology·2025

Related Experiment Video

Updated: Dec 28, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.3K

Trifecta Versus Perimount Magna Ease Aortic Valve Prostheses.

Fausto Biancari1, Antti Valtola2, Tatu Juvonen3

  • 1Heart Center, Turku University Hospital and Department of Surgery, University of Turku, Turku, Finland; Department of Surgery, Oulu University Hospital and Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, Oulu, Finland.

The Annals of Thoracic Surgery
|February 17, 2020
PubMed
Summary
This summary is machine-generated.

The Trifecta bioprosthesis showed a higher risk of repeat aortic valve replacement due to structural failure compared to the Perimount Magna Ease bioprosthesis. Further research is needed to confirm these findings on bioprosthetic valve durability.

More Related Videos

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.7K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.5K

Related Experiment Videos

Last Updated: Dec 28, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.3K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.7K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.5K

Area of Science:

  • Cardiovascular Surgery
  • Biomaterials Science
  • Medical Devices

Background:

  • Surgical bovine pericardial prostheses are frequently used for aortic valve replacement.
  • Long-term durability data for these bioprostheses remain limited.
  • Comparative outcomes between different bioprosthetic valve models require further investigation.

Purpose of the Study:

  • To compare the long-term outcomes of the Trifecta and Perimount Magna Ease bioprostheses.
  • To evaluate the risk of reoperation and prosthetic valve endocarditis between the two valve types.
  • To assess structural valve failure rates in patients undergoing aortic valve replacement.

Main Methods:

  • Comparative analysis of 2216 patients from the Finnish nationwide FinnValve registry (2008-2017).
  • Patients received either Trifecta (n=851) or Perimount Magna Ease (n=1365) bioprostheses for aortic stenosis.
  • Follow-up averaged 3.8 years; propensity score matching was used for subgroup analysis.

Main Results:

  • The Trifecta cohort exhibited a significantly higher risk of repeat aortic valve replacement for structural valve failure at 7 years (3.3% vs 0%; aSHR, 2.224).
  • Higher rates of repeat aortic valve replacement for any cause and for prosthetic valve endocarditis were observed in the Trifecta group.
  • In propensity score-matched pairs, the Trifecta group showed a higher risk of repeat aortic valve replacement for structural valve failure (5.7% vs 0%, P = .009).

Conclusions:

  • The Trifecta aortic bioprosthesis is associated with an increased incidence of repeat aortic valve replacement due to structural valve failure compared to the Perimount Magna Ease.
  • Comparative studies incorporating echocardiographic data on structural valve deterioration are necessary.
  • Longer follow-up periods are required to definitively confirm these comparative durability findings.